Referring to a Derivative of imidazo [1,2-b] pyridazine hydrochloride and imidazo [4,5-b] pyridine of formula (i), where M is an integer of 0 OR 1 to 3 X and y are n o CR7 R7 is H, halogen, alkyl, cyano, C1 - C6, among others G1 and G2 are N and C R1 and R2 is H, alkyl of C1 - C6, Oh, among others R3 is H, halogen, alkyl of C1 - C6 Among others R4 is H, alkyl haloalquilo C1 - C4, C1 - C6, among others R5 and R6 are h,Haloalquilo c1-c4 alkyl, hidroxialquilo C1 - C4, C1 - C6, among others. Preferred compounds are: 3 - oxo - 3 - ((3R) - 3 - [3 - (2 - oxo - 1.2 - dihidropiridin - 3 - il) imidazo [1,2-b] pyridazin-3 il 6] amino} - piperidin-1-yl) propanenitrile, 3 - (6 - [({1S) - 1-phenylethyl Amine} imidazo [1,2-b] pyridin-3) pyridazin-3 3 - il - 2 (1H) - One, 3 - (6 - [(1S) - 1 - (5 - fluoropiridin - 2 - il) ethyl] amino} imidazo [1,2-b] pyridazin-3 3 - il) Pyridin - 2 (1H) - One, among others.It also relates to a Pharmaceutical composition. These compounds are inhibitors of kinases JAK1, JAK2 and JAK3 and are useful in the treatment of myeloproliferative disorders, inflammatory diseases, Eye diseases, among othersREFERIDA A UN DERIVADO DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA DE FORMULA (I), DONDE: m ES 0 O UN ENTERO DE 1 A 3 X E Y SON N O CR7 R7 ES H, HALOGENO, CIANO, ALQUILO C1-C6, ENTRE OTROS G1 Y G2 SON N Y C R1 Y R2 SON H, ALQUILO C1-C6, OH, ENTRE OTROS R3 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS R4 ES H, HALOALQUILO C1-C4, ALQUILO C1-C6, ENTRE OTROS R5 Y R6 SON H, HALOALQUILO C1-C4, HIDROXIALQUILO C1-C4, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-OXO-3-((3R)-3-{[3-(2-OXO-1,2-DIHIDROPIRIDIN-3-IL)IMIDAZO[1,2-b]PIRIDAZIN-6-IL]AMINO}PIPERIDIN-1-IL)PROPANONITRILO, 3-(6-{[(1S)-1-FENILETIL AMINO}IMIDAZO[1,2-b]PIRIDAZIN-3-IL)PIRIDIN-2(1H)-ONA, 3-(6-{[(1S)-1-(5-FLUOROPIRIDIN-2-IL) ETIL]AMINO}IMIDAZO[1,2-b]PIRIDAZIN-3-IL)PIRIDIN-2(1H)-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA
